Regeneron Pharmaceuticals (REGN) Receivables (2009 - 2026)

Regeneron Pharmaceuticals' Receivables history runs 18 years deep, the most recent figure standing at $5.7 billion for Q1 2026.

• On a quarterly basis, Receivables rose 3.06% year-over-year to $5.7 billion in Q1 2026; TTM through Mar 2026 was $5.7 billion, a 3.06% increase from a year earlier, with the FY2025 full-year figure at $5.7 billion, down 7.58% from the prior year.
• Receivables held at $5.7 billion in Q1 2026 per REGN's latest filing, from $5.7 billion in the prior quarter.
• Across five years, Receivables topped out at $6.2 billion in Q4 2024 and bottomed at $4.8 billion in Q1 2022.
• The 5-year median for Receivables is $5.6 billion (2023), against an average of $5.5 billion.
• Biggest YoY gain for Receivables was 15.96% in 2022; the steepest drop was 26.25% in 2022.
• Year by year, Receivables stood at $5.3 billion in 2022, then advanced by 6.35% to $5.7 billion in 2023, then increased by 9.61% to $6.2 billion in 2024, then decreased by 7.58% to $5.7 billion in 2025, then decreased by 0.18% to $5.7 billion in 2026.
• Per Business Quant, the three latest REGN Receivables figures stand at $5.7 billion (Q1 2026), $5.7 billion (Q4 2025), and $5.7 billion (Q3 2025).